Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2026-02-27 @ 6:32 AM
Study NCT ID:
NCT02666534
Status:
COMPLETED
Last Update Posted:
2016-01-28
First Post:
2016-01-21
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efficacy of AFL-assisted PDT in Microinvasive Squamous Cell Carcinoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077442', 'term': 'Lidocaine, Prilocaine Drug Combination'}], 'ancestors': [{'id': 'D008012', 'term': 'Lidocaine'}, {'id': 'D000083', 'term': 'Acetanilides'}, {'id': 'D000813', 'term': 'Anilides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011318', 'term': 'Prilocaine'}, {'id': 'D000814', 'term': 'Aniline Compounds'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D004338', 'term': 'Drug Combinations'}, {'id': 'D004364', 'term': 'Pharmaceutical Preparations'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'FACTORIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 45}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-01'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-01', 'completionDateStruct': {'date': '2015-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-01-27', 'studyFirstSubmitDate': '2016-01-21', 'studyFirstSubmitQcDate': '2016-01-27', 'lastUpdatePostDateStruct': {'date': '2016-01-28', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2016-01-28', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Differences of Adverse events(erythema, burning sensation, swelling, bleeding) between AFL-PDT and MAL-PDT', 'timeFrame': 'Within 24 months after each treatment', 'description': 'Adverse events reported by the patients were noted at each follow-up visit, including severity, duration, and need for additional therapy. All events due to PDT were described as phototoxic reactions(e.g erythema, burning sensation, swelling, bleeding)'}], 'primaryOutcomes': [{'measure': 'Difference of short-term complete response (CR) rate between AFL-PDT and MAL-PDT', 'timeFrame': 'Short-term CR rate was evaluated at 3 months', 'description': 'The response was classified as either complete response (complete disappearance of the lesion) or incomplete response (incomplete disappearance of the lesion)'}, {'measure': 'Difference of long-term complete response (CR) rate between AFL-PDT and MAL-PDT', 'timeFrame': 'Long-term CR rate was evaluated at 24 months', 'description': 'The response was classified as either complete response (complete disappearance of the lesion) or incomplete response (incomplete disappearance of the lesion)'}, {'measure': 'Difference of recurrence rate at 24 months', 'timeFrame': 'Recurrent rate was evaluated at 24months', 'description': 'In all cases of complete response, the patients were reviewed at 24 months to check for recurrence. Post-therapy punch biopsies were performed when there was doubt concerning incomplete-response and clinical recurrence'}], 'secondaryOutcomes': [{'measure': 'Difference of the cosmetic outcome between AFL-PDT and MAL-PDT', 'timeFrame': 'Cosmetic outcome was assessed by each investigator for all lesions that achieved a complete response at 24 months', 'description': 'The overall cosmetic outcome was assessed by each investigator for all lesions that achieved complete response at 24 months, and was graded using a 4-point scale: excellent (only slight occurrence of redness or change in pigmentation), good (moderate redness or change in pigmentation), fair (slight to moderate scarring, atrophy, or induration), or poor (extensive scarring, atrophy, or induration)'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Ablative fractional laser', 'microinvasive squamous cell carcinoma', 'photodynamic therapy'], 'conditions': ['Microinvasive Squamous Cell Carcinoma']}, 'referencesModule': {'references': [{'pmid': '28199463', 'type': 'DERIVED', 'citation': 'Choi SH, Kim KH, Song KH. Effect of Methyl Aminolevulinate Photodynamic Therapy With and Without Ablative Fractional Laser Treatment in Patients With Microinvasive Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA Dermatol. 2017 Mar 1;153(3):289-295. doi: 10.1001/jamadermatol.2016.4463.'}]}, 'descriptionModule': {'briefSummary': 'Surgical excision is the standard treatment for cutaneous SCC. However, many patients diagnosed with SCC are elderly and ineligible for surgery. Ablative fractional laser- assisted photodynamic therapy (AFL-PDT) offered a higher efficacy than conventional Methylaminolevulinate (MAL)-PDT.', 'detailedDescription': "Squamous cell carcinoma (SCC) lesions are potentially metastatic and can be life threatening. Hence, surgical excision is the standard treatment for cutaneous SCC. However, some patients are ineligible for surgery because of their poor general health, concomitant anticoagulant or immunosuppressive therapies, or allergy to local anesthetics.\n\nPhotodynamic therapy (PDT) with methylaminolevulinate (MAL) is an innovative treatment modality that has been approved in Europe for the treatment of actinic keratosis, basal cell carcinoma, and Bowen's disease. However, currently, there is insufficient evidence to support the routine use of topical PDT for SCC.\n\nAblative fractional laser (AFL) ablates the epidermis and dermis without significant thermal injury, creating microscopic ablation zones in the portion of the skin that the laser is applied to. Our previous studies showed that AFL-primed MAL-PDT (AFL-PDT) offered a higher efficacy than conventional MAL-PDT in the treatment of many other diseases, such as actinic keratosis, actinic cheilitis, and Bowen's disease.\n\nInvestigators recruited Korean patients with microinvasive SCC and compared the efficacy, recurrence rate, and cosmetic outcomes of AFL-PDT with those of standard MAL-PDT."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['OLDER_ADULT'], 'maximumAge': '89 Years', 'minimumAge': '65 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients aged 18 years or more who had previously untreated microinvasive SCC, providing they satisfied both of the following conditions:\n\n * tumor invasion into the papillary dermis (Clark level II) according to a biopsy specimen and\n * difficulty in surgical excision because of health problems (bleeding tendency or cardiac problems)\n\nExclusion Criteria:\n\n* pregnancy or lactation\n* active systemic infectious disease\n* other inflammatory, infectious, or neoplastic skin diseases in the treated area\n* allergy to MAL,other topical photosensitizers, or excipients of the cream\n* history of photosensitivity\n* use of immunosuppressive or photosensitizing drugs\n* participation in any other investigational study in the preceding 30 days\n* history or indicators of poor compliance\n* Histological findings of acantholysis, desmoplasia, perineural or lymphovascular invasion, and echographic features of regional lymph node metastasis were the disease-specific exclusion criteria'}, 'identificationModule': {'nctId': 'NCT02666534', 'briefTitle': 'Efficacy of AFL-assisted PDT in Microinvasive Squamous Cell Carcinoma', 'organization': {'class': 'OTHER', 'fullName': 'Dong-A University'}, 'officialTitle': 'A Randomised Trial Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Ablative Fractional Laser Treatment in Patients With Microinvasive Squamous Cell Carcinoma: Results From a 24-month Follow-up', 'orgStudyIdInfo': {'id': 'DAUderma-05'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'AFL-PDT', 'description': 'Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)', 'interventionNames': ['Drug: lidocaine-prilocaine 5% cream application', 'Device: 2940-nm Er:YAG AFL pretreatment', 'Drug: methyl-aminolevulinate application', 'Device: Illuminating using red light-emitting diode lamps']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'MAL-PDT', 'description': 'Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)', 'interventionNames': ['Drug: methyl-aminolevulinate application', 'Device: Illuminating using red light-emitting diode lamps']}], 'interventions': [{'name': 'lidocaine-prilocaine 5% cream application', 'type': 'DRUG', 'description': 'The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion', 'armGroupLabels': ['AFL-PDT']}, {'name': '2940-nm Er:YAG AFL pretreatment', 'type': 'DEVICE', 'description': 'After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse', 'armGroupLabels': ['AFL-PDT']}, {'name': 'methyl-aminolevulinate application', 'type': 'DRUG', 'description': "Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.", 'armGroupLabels': ['AFL-PDT', 'MAL-PDT']}, {'name': 'Illuminating using red light-emitting diode lamps', 'type': 'DEVICE', 'description': 'Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.', 'armGroupLabels': ['AFL-PDT', 'MAL-PDT']}]}, 'contactsLocationsModule': {'locations': [{'zip': '602-715', 'city': 'Busan', 'state': 'Dong Dae Sin-dong, Seo-gu', 'country': 'South Korea', 'facility': 'Dong-A University', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Dong-A University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Associate professor', 'investigatorFullName': 'Song Ki-Hoon', 'investigatorAffiliation': 'Dong-A University'}}}}